Anglonordic Life Science 2026: A focus on execution
The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.
Newsletters and Deep Dive digital magazine
The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.
Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
In another setback for abortion care in the US, an appeals court has issued an order restricting the distribution of mifepristone through the mail.
The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.
Editor's Picks
Newsletters and Deep Dive
digital magazine